CABP4

Across TCGA pan-cancer cohorts, CABP4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CABP4 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CABP4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CABP4 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

BLCA, SKCM, and UCEC are the cancer types where CABP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.141	0.574	.005	24	view →
SKCM	OS	Median	III,IV	0.261	0.848	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	OS	Median	III,IV	0.501	0.629	.032	2	view →
LUSC	DFS	Median	All	0.872	0.385	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CABP4–BLCA (DFS)

Open the BLCA breakdown →